靶向线粒体蛋白转位酶TIM44鉴定结直肠癌治疗性自噬的荧光小分子增强剂
本研究合成并筛选线粒体靶向近红外荧光探针,鉴定出新型自噬增强剂IR-58,其优先蓄积于结直肠癌细胞线粒体,通过ROS-Akt-mTOR通路诱导过度自噬和凋亡,并首次发现TIM44为潜在癌基因,与结直肠癌进展和不良预后正相关。
要点
- IR-58是肿瘤选择性近红外自噬增强剂,可整合成像与治疗。
- IR-58通过抑制TIM44-SOD2通路增加ROS,诱导过度自噬和凋亡。
- TIM44表达与结直肠癌发展及不良预后正相关,为潜在癌基因。
核心结论
- 开发出具有线粒体靶向成像和治疗能力的新型近红外小分子自噬增强剂IR-58用于结直肠癌治疗。
- 首次鉴定TIM44为潜在癌基因,通过TIM44-SOD2-ROS-mTOR通路在自噬中起重要作用。
研究设计与样本
- 合成一系列线粒体靶向近红外荧光团并筛选自噬增强活性。
- 在体外和体内检测光学性质与生物学效应。
- 使用抑制剂、小干扰RNA、RNA测序、质谱和人样本研究机制。
主要发现
- IR-58优先蓄积于结直肠癌细胞和异种移植瘤的线粒体,该过程依赖糖酵解和有机阴离子转运多肽。
- IR-58通过诱导过度自噬杀伤肿瘤细胞并诱导凋亡,由ROS-Akt-mTOR通路介导。
- RNA测序、质谱和siRNA干扰研究表明TIM44-SOD2通路抑制导致IR-58诱导的过量ROS、自噬和凋亡。
- TIM44表达与患者结直肠癌发展和不良预后正相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As the modulation of autophagic processes can be therapeutically beneficial to cancer treatment, the identification of novel autophagic enhancers is highly anticipated. However, current autophagy-inducing anticancer agents exert undesired side effects owing to their non-specific biodistribution in off-target tissues. This study aims to develop a multifunctional agent to integrate cancer targeting, imaging and therapy and to investigate its mechanism. DESIGN: A series of mitochondria-targeting near-infrared (NIR) fluorophores were synthesised, screened and identified for their autophagy-enhancing activity. The optical properties and biological effects were tested both in vitro and in vivo. The underlying mechanism was investigated using inhibitors, small interfering RNA (siRNA), RNA sequencing, mass spectrometry and human samples. RESULTS: We have screened and identified a new NIR autophagy-enhancer, IR-58, which exhibits significant tumour-selective killing effects. IR-58 preferentially accumulates in the mitochondria of colorectal cancer (CRC) cells and xenografts, a process that is glycolysis-dependent and organic anion transporter polypeptide-dependent. IR-58 kills tumour cells and induces apoptosis via inducing excessive autophagy, which is mediated through the reactive oxygen species (ROS)-Akt-mammalian target of rapamycin (mTOR) pathway. RNA sequencing, mass spectrometry and siRNA interference studies demonstrate that translocase of inner mitochondrial membrane 44 (TIM44)-superoxide dismutase 2 (SOD2) pathway inhibition is responsible for the excessive ROS, autophagy and apoptosis induced by IR-58. TIM44 expression correlates positively with CRC development and poor prognosis in patients. CONCLUSIONS: A novel NIR small-molecule autophagy-enhancer, IR-58, with mitochondria-targeted imaging and therapy capabilities was developed for CRC treatment. Additionally, TIM44 was identified for the first time as a potential oncogene, which plays an important role in autophagy through the TIM44-SOD2-ROS-mTOR pathway.
引用
- Huang Y, Zhou J, Luo S, et al. Identification of a fluorescent small-molecule enhancer for therapeutic autophagy in colorectal cancer by targeting mitochondrial protein translocase TIM44. Gut. 2016. PMID: 27849558. doi:10.1136/gutjnl-2016-311909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。